Form 4 for MRK Merck & Co.
Accepted 2022-05-05 00:00:00 ET · period of report 2022-05-03 · accession 0001127602-22-013535 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-05 | 2022-05-04 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | F - Tax | $87.10 | -326 | 41.1K | -0.8% | -$28.4K |
| D | 2022-05-05 | 2022-05-04 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $87.10 | +949 | 41.4K | +2% | +$82.7K |
| DM | 2022-05-05 | 2022-05-03 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | A - Grant | $0.00 | +16.0K | 2,411 | New | $0 |
| D | 2022-05-05 | 2022-05-04 | MRK | Karachun Rita A | SVP Fince-Gbl Ctrl | M - OptEx | $0.00 | -949 | 1,900 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-04 | F | D | 326 | $87.10 | 41,102.97 | D | — | — | (F1) Holdings include shares acquired in dividend reinvestment transactions. |
| 2 | Common | Common Stock | 2022-05-04 | M | A | 949 | $87.10 | 41,428.97 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-05-03 | A | A | 13,592 | $0.00 | 13,592 | D | $87.10 · 2023-05-03 to 2032-05-02 | 13,592 Common Stock | (F2) The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. |
| 4 | Derivative | Restricted Stock Unit | 2022-05-04 | M | D | 949 | $0.00 | 1,900 | D | — · 2022-05-04 to 2024-05-04 | 949 Common Stock | (F5) Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. (F3) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. (F6) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. |
| 5 | Derivative | Restricted Stock Unit | 2022-05-03 | A | A | 2,411 | $0.00 | 2,411 | D | — · 2023-05-03 to 2025-05-03 | 2,411 Common Stock | (F3) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. (F4) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. |